Payment overview · 2025
General Payments
$1,619.33
98 reported records · 17 companies
Healthcare provider profile · identity verified
Samuel R Carter, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JOPLIN, MO · NPI 1760428973
Verified facts
What the public records show
CMS Open Payments records show Samuel R Carter, MD received $1,619.33 in general payments during 2025 across 98 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 234 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 249 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 234 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $269.40 | 16.6% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $166.08 | 10.3% | 11 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $164.85 | 10.2% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $161.82 | 10.0% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $147.15 | 9.1% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $147.12 | 9.1% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $135.20 | 8.3% | 11 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $87.28 | 5.4% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $76.26 | 4.7% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $68.92 | 4.3% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.09 | 2.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.36 | 2.2% | 2 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $30.16 | 1.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.22 | 1.8% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $26.66 | 1.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.29 | 0.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $13.47 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,619.33 | 98 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $255.61 | 13 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $166.08 | 11 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $164.85 | 10 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $161.82 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $150.15 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $121.67 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $112.35 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $99.03 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $97.81 | 8 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $87.28 | 4 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $76.26 | 4 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $68.92 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $48.09 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $46.22 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.09 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $43.08 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $36.36 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $36.36 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.80 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.46 | 2 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $30.16 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.22 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $26.66 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $26.66 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.86 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| ONZETRA XSAIL Normalized: onzetra xsail |
Drug | Currax Pharmaceuticals LLC | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.53 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.53 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.53 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 196 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 234 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 105 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 146 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 115 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
88 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
234 | 41 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
249 | 249 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
61 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
115 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
234 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
105 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
146 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
196 | 30 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1314 | 357 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1158 | 280 |
| Amlodipine Besylate | Amlodipine Besylate | 975 | 251 |
| Losartan Potassium | Losartan Potassium | 675 | 183 |
| Lisinopril | Lisinopril | 667 | 183 |
| Atorvastatin Calcium | Atorvastatin Calcium | 645 | 168 |
| Pantoprazole Sodium | Pantoprazole Sodium | 601 | 154 |
| Metoprolol Succinate | Metoprolol Succinate | 470 | 123 |
| Omeprazole | Omeprazole | 405 | 111 |
| Metformin Hcl | Metformin Hcl | 369 | 108 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 318 | 86 |
| Zolpidem Tartrate | Zolpidem Tartrate | 304 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 257 | 70 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 249 | 249 |
| Citalopram Hbr | Citalopram Hydrobromide | 237 | 62 |
| Jardiance | Empagliflozin | 234 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 233 | 59 |
| Carvedilol | Carvedilol | 227 | 56 |
| Allopurinol | Allopurinol | 222 | 59 |
| Eliquis | Apixaban | 196 | 30 |
| Ezetimibe | Ezetimibe | 195 | 56 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 182 | 52 |
| Montelukast Sodium | Montelukast Sodium | 181 | 55 |
| Pioglitazone Hcl | Pioglitazone Hcl | 178 | 42 |
| Gabapentin | Gabapentin | 174 | 43 |
| Furosemide | Furosemide | 160 | 52 |
| Potassium Chloride | Potassium Chloride | 158 | 46 |
| Glimepiride | Glimepiride | 154 | 41 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 152 | 39 |
| Paroxetine Hcl | Paroxetine Hcl | 147 | 38 |
| Ozempic | Semaglutide | 146 | 23 |
| Meloxicam | Meloxicam | 138 | 45 |
| Bupropion Xl | Bupropion Hcl | 133 | 31 |
| Alendronate Sodium | Alendronate Sodium | 130 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 129 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 115 | 20 |
| Spironolactone | Spironolactone | 109 | 35 |
| Estradiol | Estradiol | 105 | 30 |
| Mounjaro | Tirzepatide | 105 | 21 |
| Alprazolam | Alprazolam | 104 | 35 |
| Tramadol Hcl | Tramadol Hcl | 95 | 27 |
| Buspirone Hcl | Buspirone Hcl | 93 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 22 |
| Synthroid | Levothyroxine Sodium | 88 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 19 |
| Atenolol | Atenolol | 78 | 21 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 76 | 17 |
| Propranolol Hcl | Propranolol Hcl | 75 | 17 |
| Trazodone Hcl | Trazodone Hcl | 73 | 17 |
| Finasteride | Finasteride | 66 | 19 |
| Irbesartan | Irbesartan | 62 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 32 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 61 | 35 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 60 | 60 |
| Fenofibrate | Fenofibrate | 60 | 15 |
| Farxiga | Dapagliflozin Propanediol | 59 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 13 |
| Colestipol Hcl | Colestipol Hcl | 57 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 19 |
| Sertraline Hcl | Sertraline Hcl | 55 | 15 |
| Xarelto | Rivaroxaban | 55 | 13 |
| Azithromycin | Azithromycin | 54 | 50 |
| Donepezil Hcl | Donepezil Hcl | 54 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 54 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 52 | suppressed |
| Simvastatin | Simvastatin | 45 | 11 |
| Celecoxib | Celecoxib | 44 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 20 |
| Famotidine | Famotidine | 44 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 34 |
| Eszopiclone | Eszopiclone | 40 | suppressed |
| Trulicity | Dulaglutide | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 38 | suppressed |
| Valsartan | Valsartan | 38 | 12 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Dexilant | Dexlansoprazole | 25 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | 11 |
| Carisoprodol | Carisoprodol | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Eplerenone | Eplerenone | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 16 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 16 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Livalo | Pitavastatin Calcium | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Loteprednol Etabonate | Loteprednol Etabonate | 13 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,619.33 · 98 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, Auvelity, BREZTRI, CAPVAXIVE, COMIRNATY, CONTRAVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE, Fluad, Flucelvax, GARDASIL 9, GEMTESA, JARDIANCE, MOUNJARO, NURTEC ODT, ONZETRA XSAIL, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, Wegovy, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error